Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Topical Naltrexone Is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds.

McLaughlin PJ, Cain JD, Titunick MB, Sassani JW, Zagon IS.

Adv Wound Care (New Rochelle). 2017 Sep 1;6(9):279-288. doi: 10.1089/wound.2016.0725.

2.

The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.

Sassani JW, Mc Laughlin PJ, Zagon IS.

J Diabetes Res. 2016;2016:9703729. Epub 2016 Sep 14. Review.

3.

Topical Application of Naltrexone to the Ocular Surface of Healthy Volunteers: A Tolerability Study.

Liang D, Sassani JW, McLaughlin PJ, Zagon IS.

J Ocul Pharmacol Ther. 2016 Mar;32(2):127-32. doi: 10.1089/jop.2015.0070. Epub 2016 Jan 7.

PMID:
26741052
4.

Secondary corneal amyloidosis after perforating corneal trauma: A series of 5 cases and review of the literature.

Saleh S, Brownstein S, Manusow JS, Jastrzebski A, Lam K, Sassani JW, Mintsioulis G, Gilberg SM.

Surv Ophthalmol. 2015 Nov-Dec;60(6):590-5. doi: 10.1016/j.survophthal.2015.07.004. Epub 2015 Aug 4. Review.

PMID:
26253297
5.

Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone.

Zagon IS, Sassani JW, Immonen JA, McLaughlin PJ.

Clin Exp Ophthalmol. 2014 Mar;42(2):159-68. doi: 10.1111/ceo.12144. Epub 2013 Jul 29.

PMID:
23777539
6.

Spontaneous episodic decreased tear secretion in rats is related to opioidergic signaling pathways.

Zagon IS, Campbell AM, Sassani JW, McLaughlin PJ.

Invest Ophthalmol Vis Sci. 2012 May 31;53(6):3234-40. doi: 10.1167/iovs.11-9051.

7.

Failure of radiation therapy in orbital xanthogranuloma.

Ebrahimi KB, Miller NR, Sassani JW, Iliff NT, Green WR.

Ophthalmic Plast Reconstr Surg. 2010 Jul-Aug;26(4):259-64. doi: 10.1097/IOP.0b013e3181bd4356.

PMID:
20502363
8.

Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis.

Klocek MS, Sassani JW, Donahue RN, McLaughlin PJ, Zagon IS.

Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5054-61. doi: 10.1167/iovs.09-4949. Epub 2010 May 12.

9.

Linkage of posterior amorphous corneal dystrophy to chromosome 12q21.33 and exclusion of coding region mutations in KERA, LUM, DCN, and EPYC.

Aldave AJ, Rosenwasser GO, Yellore VS, Papp JC, Sobel EM, Pham MN, Chen MC, Dandekar S, Sripracha R, Rayner SA, Sassani JW, Gorin MB.

Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4006-12. doi: 10.1167/iovs.09-4067. Epub 2010 Mar 31.

10.

Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus.

Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ.

Arch Ophthalmol. 2009 Nov;127(11):1468-73. doi: 10.1001/archophthalmol.2009.270.

11.

Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits.

Zagon IS, Sassani JW, Carroll MA, McLaughlin PJ.

Brain Res Bull. 2010 Feb 15;81(2-3):248-55. doi: 10.1016/j.brainresbull.2009.10.009. Epub 2009 Oct 21.

12.

Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.

McLaughlin PJ, Sassani JW, Klocek MS, Zagon IS.

Brain Res Bull. 2010 Feb 15;81(2-3):236-47. doi: 10.1016/j.brainresbull.2009.08.008. Epub 2009 Aug 14. Review.

13.

Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats.

Klocek MS, Sassani JW, McLaughlin PJ, Zagon IS.

Exp Eye Res. 2009 Nov;89(5):686-92. doi: 10.1016/j.exer.2009.06.010. Epub 2009 Jul 1.

14.

Prevention of exuberant granulation tissue and neovascularization in the rat cornea by naltrexone.

Zagon IS, Klocek MS, Griffith JW, Sassani JW, Komáromy AM, McLaughlin PJ.

Arch Ophthalmol. 2008 Apr;126(4):501-6. doi: 10.1001/archopht.126.4.501.

15.

Health administration education for physicians: why?

Ziegenfuss JT Jr, Sassani JW.

Am J Med Qual. 2008 Jan-Feb;23(1):5-6. doi: 10.1177/1062860607310775. No abstract available.

PMID:
18187585
16.

Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus.

Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ.

Arch Ophthalmol. 2007 Aug;125(8):1082-8.

PMID:
17698755
17.

Topically applied naltrexone restores corneal reepithelialization in diabetic rats.

Klocek MS, Sassani JW, McLaughlin PJ, Zagon IS.

J Ocul Pharmacol Ther. 2007 Apr;23(2):89-102.

PMID:
17444796
18.

Naltrexone accelerates healing without compromise of adhesion complexes in normal and diabetic corneal epithelium.

Zagon IS, Sassani JW, Myers RL, McLaughlin PJ.

Brain Res Bull. 2007 Apr 2;72(1):18-24. Epub 2007 Jan 8.

PMID:
17303503
19.

Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA.

Zagon IS, Sassani JW, Malefyt KJ, McLaughlin PJ.

Arch Ophthalmol. 2006 Nov;124(11):1620-4.

PMID:
17102011
20.

Corneal safety of topically applied naltrexone.

Zagon IS, Klocek MS, Sassani JW, Mauger DT, McLaughlin PJ.

J Ocul Pharmacol Ther. 2006 Oct;22(5):377-87.

PMID:
17076633

Supplemental Content

Loading ...
Support Center